Stock Talk
Kinross Gold (KGC)
"Over the last four quarters, the company has surpassed consensus EPS estimates four times."
Update " Gold is breaching the $2400 mark this morning.
Previous note and trend points to stay with Kinross Gold miner.
"Jones Note: With Gold trending higher, now over $2300 the trend is pointing to higher gold, possibly towards $2500 in the near. KGC seems on path for higher share levels and it pays a divy while we wait."
__________
Next up for Stock talk ...
Oncolytics Biotech, Inc. (ONCY)
Update: To better understand why some follow ONCY stock, plug in - "What is Pelareorep" into AI- Chat GPT. It's all about delivering the mechanism of action (MoA) of "Pela" to help cancer patients to activate and enhance their very own immune system to fight cancer. Complete Responses (CR) have been reported in two cases, one being serious Pancreatic cancer.
_______
"Pelareorep, also known as Reolysin, is a propietary formulation of the reovirus which is a naturally occurring virus that can infect and kill cancer cells. It is being developed by Oncolytics Biotech Inc, for the treatment of various types of cancer. The therapy works by selectively targeting and replicating within cancer cells, therby enhancing the anti-tumor immune response. This dual mechanism of action has shown promise in preclinical and clinical studies, particularly when combined with other cancer therapies such as checkpoint inhibitors and chemotherapy." - AI- Chat GPT.
_______
Jones report view: ONCY holds all the patents on Pelareorep. For risk aware investors holding a few shares of ONCY, at just over a buck a share may pay off in a big way as Pelareorep advances further. Several upcoming studies are in planning to further confirm the Mechanism of Action (MoA). Yes, it's all about confirming the MoA in several cancer indications. Pancreatic cancer is the ultimate test and if the planned study with Pela and the checkpoint inhibitor shows similar or better results than past studies, where a Complete Response (CR) was reported, watch ONCY stock.
ONCY has been around a long time with checkered results... BUT the addition of a checkpoint inhibitor that suppresses the protein side of the immune system to slow Pelareorep from targeting and lysing cancer cells has new potential to be a fast-acting response treatment. Some data on the ONCY website points to weeks, not years, for the MoA to show positive results in seriously ill patients. Pela may indeed improve lives to live longer and stronger employing their very own immune system by activating their T Fighter cells to replicate and actually KILL Cancer cells.
Note: The small biotech space is risky business. For this reason, no more than a small retail investor can afford to lose is the prudent approach. There are realities of the market and space to deal with as ONCY pursues the path to success.
Stay tuned for more on Stocks to Watch.
For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time. But trying to look ahead a few months into the future may be a way to do things. If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor. In all - we use the word maybe "some", not "too much" and play it accordingly. Remember never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.
With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.
_____________
